Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
RecruitingOBSERVATIONAL
Enrollment
600
Participants
Timeline
Start Date
October 26, 2023
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
Conditions
HER2-positive Breast Cancer
Trial Locations (1)
Unknown
RECRUITING
Keda Yu, Shanghai
All Listed Sponsors
lead
Fudan University
OTHER
NCT06161922 - Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy | Biotech Hunter | Biotech Hunter